RxDoctor Payments Data

Stephanie Bailey, APRN

Nurse Practitioner · Seminole, FLNPI 1720724115

Payments from drug & device makers

$1,413in general payments, 2019–2025

Across 34 payments — averaging $41.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$385
  • AbbVie$354
  • Sumitomo Pharma America, Inc.$178
  • Neurocrine Biosciences, Inc.$121
  • Astellas Pharma US Inc$96
  • Almatica Pharma LLC$58
  • plus $222 from 8 others

What the payments were for

  • Food & beverage$1,413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,413 in reported general payments places this provider in the 75th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$20,275
Medicare patients
51
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$13,717
LinzessLinaclotide23$12,182
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,281
JardianceEmpagliflozin15$8,666
FarxigaDapagliflozin Propanediol11$6,766
MyrbetriqMirabegron13$5,958
VascepaIcosapent Ethyl14$4,819
Ketoconazole20$1,061
Ventolin HfaAlbuterol Sulfate15$884
Levothyroxine Sodium89$841
Lisinopril123$679
Medroxyprogesterone Acetate11$646
Atorvastatin Calcium100$604
Rosuvastatin Calcium35$539
Albuterol Sulfate HfaAlbuterol Sulfate13$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$354$12,18223 claims
AstraZenecaFarxiga$385$6,76611 claims
Astellas Pharma US IncMyrbetriq$96$5,95813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Seminole

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →